This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Phase 3Recruiting
- Lead sponsor
- Pfizer (Industry)
- Enrollment
- 1,000 (estimated)
- Start date
- 28 Sep 2025
- Primary completion
- 12 Sep 2028 (estimated)
- Study completion
- 8 Dec 2034
- Last update posted
- 14 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Mevrometostat Drug
- Placebo Drug
- Enzalutamide Drug
Conditions and primary outcome
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Hormone Sensitive Prostate Cancer
- Prostate Cancer
- Cancer of the Prostate
Primary outcome
Radiographic Progression Free Survival (rPFS) (Randomization up to approximately 4 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07028853.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07028853 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.